Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Chondrosarcoma 2Sinonasal undifferentiated carcinoma 1Immunoblastic Lymphadenopathy 1Glioma 1Esthesioneuroblastoma, Olfactory 1Cholangiocarcinoma 1

Interventions

fludarabine phosphate 16Peripheral Blood Stem Cell Transplantation 16Whole-Body Irradiation 14Mycophenolic Acid 11Cyclosporine 11Cyclophosphamide 9Busulfan 6Melphalan 5Antilymphocyte Serum 5Tacrolimus 4Etoposide 4Therapeutics 3Radiotherapy 3Methylprednisolone 3Methotrexate 3Thiotepa 2Carboplatin 2Alemtuzumab 2thymoglobulin 1tanespimycin 1ontuxizumab 1obatoclax 1merphos 1liposomal amphotericin B 1imetelstat 1ganitumab 1etoposide phosphate 1entinostat 1enasidenib 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoblastic Lymphadenopathy × enasidenib × Sarcoma × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡